Zusammenfassung
Die zunehmende Prävalenz und steigende krankheitsbedingte Kosten machen die chronische Herzinsuffizienz zu einer wachsenden sozioökonomischen Herausforderung. Nur durch ein therapeutisches Zusammenwirken von leitliniengerechter Herzinsuffizienztherapie und ganzheitlicher Patientenbetreuung können Mortalität, Morbidität, Leistungsfähigkeit und Lebensqualität verbessert werden. Eine ganzheitliche Patientenversorgung beinhaltet neben der medikamentösen und chirurgischen Therapie die Berücksichtigung von Komorbiditäten und individuellen Bedürfnissen, Lebensstilberatung und multidisziplinäre Managementprogramme bei Hochrisikopatienten. Darüber hinaus ist für eine optimale Patientenbetreuung wichtig, dass eine „nahtlose“ stationäre und ambulante Versorgungsstruktur gewährleistet wird. Bei Herzinsuffizienzpatienten müssen auch palliative Bedürfnisse berücksichtigt werden, die derzeit noch zu wenig Beachtung finden.
Abstract
The rising prevalence and increasing disease-related costs render chronic heart failure a rapidly growing socioeconomic challenge. The concerted action of guideline-adjusted therapy and holistic patient care is essential to achieve improvements in mortality, morbidity, functional status and quality of life of patients with symptomatic heart failure. Holistic care strategies comprise consideration of comorbidities and individual needs, lifestyle recommendations and multidisciplinary management programs for high-risk symptomatic patients in addition to basic medication and surgical therapies. For optimal patient care and coaching, seamless interaction is required between in-hospital treatment and outpatient facilities. Moreover, the palliative needs of heart failure patients need to be considered, a topic that is currently not receiving enough attention.
Literatur
Angermann CE, Gelbrich G, Stork S et al (2007) Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 9:1212–1222
Angermann CE, Stork S, Gelbrich G et al (2012) Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail 5:25–35
Anker SD, Comin Colet J, Filippatos G et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448
Palliative Care Alliance and World Health Organization (2014) Global Atlas of Palliative Care at the End of Life
World Health Organization (o J) WHO definition of palliative care
Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233
Brenner S, Guder G, Berliner D et al (2013) Airway obstruction in systolic heart failure – COPD or congestion? Int J Cardiol 168:1910–1916
Cleland JG, Cohen-Solal A, Aguilar JC et al (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360:1631–1639
Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32:2395–2404
Faller H, Angermann CE (2008) Depression in chronic heart failure: complication, risk factor or autonomous disease? Internist (Berl) 49:394, 396–398, 400, 402–404
Ghoorah K, Campbell P, Kent A et al (2014) Obesity and cardiovascular outcomes: a review. Eur Heart J Acute Cardiovasc Care (im Druck)
Gielen S, Landmesser U (2014) The year in cardiology 2013: cardiovascular disease prevention. Eur Heart J 35:307–312
Goodlin SJ (2009) Palliative care in congestive heart failure. J Am Coll Cardiol 54:386–396
Hernandez AV, Usmani A, Rajamanickam A et al (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115–128
Jaarsma T, Beattie JM, Ryder M et al (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:433–443
Klip IT, Comin-Colet J, Voors AA et al (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165:575–582.e573
Krumholz HM, Baker DW, Ashton CM et al (2000) Evaluating quality of care for patients with heart failure. Circulation 101:E122–E140
Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357
McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490
Neumann T, Biermann J, Erbel R et al (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 106:269–275
Silverberg DS, Wexler D, Iaina A et al (2006) The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26:296–306
Solomon SD, Dobson J, Pocock S et al (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482–1487
Stork S, Faller H, Schowalter M et al (2009) Evidence-based disease management in patients with heart failure (HeartNetCare-HF Würzburg). Dtsch Med Wochenschr 134:773–776
Stork S, Hense HW, Zentgraf C et al (2008) Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail 10:1236–1245
Swedberg K, Young JB, Anand IS et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:1210–1219
Takeda A, Taylor SJ, Taylor RS et al (2012) Clinical service organisation for heart failure. Cochrane Database Syst Rev 9:CD002752
Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e327
Einhaltung ethischer Richtlinien
Interessenkonflikt. C. Feldmann, G. Ertl und C.E. Angermann geben an, dass kein Interessenkonflikt besteht. Die wissenschaftliche Arbeit der Autoren wird oder wurde von folgenden Firmen/Einrichtungen finanziell unterstützt: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Lundbeck, Merck, Sharp & Dohme, Novartis, Pfizer, ResMed, Roche, Siemens und Vifor. C.E. Angermann erhält Berater- oder Vortragshonorare von den Firmen Bayer, Biotronik, Merck, Sharp & Dohme, Servier, Novartis, Pfizer und ResMed. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Additional information
Der Erinnerung an Prof. Dr. Dr. h. c. mult. Kurt Kochsiek gewidmet.
Rights and permissions
About this article
Cite this article
Feldmann, C., Ertl, G. & Angermann, C. Ganzheitliche Behandlung der chronischen Herzinsuffizienz. Internist 55, 676–686 (2014). https://doi.org/10.1007/s00108-013-3427-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-013-3427-0